Veterinary Precision Oncology
Personalised mRNA Cancer Vaccines for Dogs
A vaccine designed for your dog's specific tumour. The same science in Phase III human clinical trials — available for dogs today.
Based in Switzerland. Operating under Formula magistralis regulatory framework.
The Treatment Gap
Personalised mRNA cancer vaccines are already transforming human oncology. In clinical trials, they have reduced melanoma recurrence by 49% at five-year follow-up. Patients with pancreatic cancer and triple-negative breast cancer have remained disease-free for over six years. The first regulatory approvals for humans are expected in 2027–2028.
But human medicine moves slowly by design. Clinical trials take years. Approvals cost hundreds of millions. The full potential of this technology will take a decade to reach most patients.
Dogs face no such constraints. They can be treated today — under existing veterinary regulatory frameworks — with the same underlying science. The mRNA platform is identical. The cancer biology is remarkably similar. The US National Cancer Institute has validated dogs as translational models for human cancer.
One in four dogs develops cancer. Dog owners already spend thousands on conventional treatments that deliver palliative outcomes at best. They deserve access to better science.
From Tumour to Treatment in Five Steps
Every vaccine is unique because every tumour is unique. We coordinate the entire pipeline — you and your vet handle the first and last step.
Biopsy
Your vet takes a tumour biopsy and ships the sample to a genomic sequencing laboratory.
Sequence
The tumour and healthy tissue are sequenced to identify the somatic mutations driving the cancer.
Predict
Computational analysis identifies 15–20 mutations most likely to trigger an immune response against the tumour.
Manufacture
A custom mRNA vaccine encoding those mutations is synthesised and formulated in lipid nanoparticles — the same delivery technology used in COVID-19 vaccines.
Treat
The vaccine is shipped under cold chain to your vet, who administers it. Follow-up imaging tracks the tumour response.
Typical timeline: 4–6 weeks from biopsy to first injection
Which Cancers Respond Best
Personalised mRNA vaccines can target any solid tumour that can be biopsied and sequenced. Some cancer types are better suited than others.
Mast Cell Tumours
The most common malignant skin tumour in dogs. Well-characterised driver mutations (KIT, GNB1) make neoantigen prediction particularly tractable.
Learn more →Melanoma
Oral melanoma is aggressive and often metastatic. Canine melanoma shares key molecular features with human melanoma — the cancer type with the strongest human vaccine data.
Learn more →Osteosarcoma
The most common primary bone tumour in large breeds. Mirrors human osteosarcoma in genomic landscape. Known drivers include TP53 in 71% of cases.
Learn more →Get an Honest Assessment for Your Dog
Tell us about your dog's diagnosis. We'll respond within 48 hours.
Every Treated Dog Advances the Science
Every dog we treat teaches us something new. Each case generates data — which mutations were targeted, how the immune system responded, whether the tumour shrank — that makes the next vaccine smarter. Over time, this growing body of evidence helps us predict which dogs are most likely to benefit and which neoantigen combinations work best.
This is the same principle behind the most successful precision oncology programmes in human medicine: each patient's outcome improves the treatment for the next. Your dog's case doesn't just help your dog. It helps every dog that comes after.
Founding Patient Programme
The first dogs treated through this platform are not just patients — they are partners in proving the concept. In exchange for full documentation, follow-up imaging, and permission to publish the case anonymously, the Founding Patient Programme offers treatment at preferential terms.
Places are limited. The programme is designed for dogs with confirmed cancer diagnoses where conventional treatments have been exhausted or are insufficient.
We will respond within 48 hours with an honest assessment of your dog's candidacy.
Start with a Conversation
Whether you are a dog owner exploring options, or a veterinarian considering a referral, we are happy to discuss your specific situation — honestly and without obligation.
Response within 48 hours. No treatment begins without full informed consent.